Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06552000). This is a study registration, not published results. Lead sponsor: University of Texas Southwestern Medical Center. Recruitment status: WITHDRAWN. Phase: NA. Study type: INTERVENTIONAL. Conditions: NSCLC, Non Small Cell Lung Cancer. Interventions: DEVICE: NovoTTF-200T System. Primary outcome measures: Effect of TTF (Tumor-Treating Fields) on Fanconi anemia-related genes. , approximately 14-28 days. Brief summary: The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC). TTField is a non-invasive treatment that uses low-intensity electrical fields to treat cancer. Resection is the medical term for surgically removing part or all of a tissue, structure, or organ.